Pyridostigmine Bromide

Images are for illustration purposes only;
actual packaging may vary.

Pyridostigmine Bromide is a cholinesterase inhibitor primarily used to improve muscle strength in patients with myasthenia gravis, a chronic autoimmune neuromuscular disorder. By inhibiting the breakdown of acetylcholine, it enhances neuromuscular transmission, thereby alleviating symptoms such as muscle weakness and fatigue.

In addition to its primary use, Pyridostigmine Bromide is also employed in the management of certain types of orthostatic hypotension and as a prophylactic treatment against nerve agent exposure. Its versatility in treating various conditions makes it a valuable component in compounded formulations tailored to meet specific patient needs.

Trusted by 60,357 patients to date.

A group of faces of our past satisfied patients.

Custom made in our compounding labs.

Personalized treatment for better results.

All strengths and ingredients are tailored to your needs.

This medication is not available at retail pharmacies. It is compounded, and may be more effective at treating you or your patient.

This is some text inside of a div block.

Heading 1

Heading 2

Heading 3

Heading 4

Heading 5

Heading 6

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Block quote

Ordered list

Item 1
Item 2
Item 3

Unordered list

Item A
Item B
Item C

Text link

Bold text

Emphasis

^Superscript

_Subscript

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Active Ingredient Information

Pyridostigmine Bromide is a cholinesterase inhibitor that plays a crucial role in the management of myasthenia gravis, a neuromuscular disorder characterized by weakness and rapid fatigue of voluntary muscles. By inhibiting the breakdown of acetylcholine, Pyridostigmine Bromide enhances neuromuscular transmission, thereby improving muscle strength and reducing symptoms associated with this condition.

In addition to its primary use in myasthenia gravis, Pyridostigmine Bromide is also utilized in the treatment of certain cases of orthostatic hypotension and as a prophylactic agent against nerve agent poisoning. Its pharmacokinetic profile includes oral bioavailability, with peak plasma concentrations typically reached within 1 to 2 hours post-administration, and a half-life of approximately 1 to 2 hours, necessitating multiple daily doses for sustained therapeutic effect.

Prescribers should be aware of potential side effects, which may include gastrointestinal disturbances, increased salivation, and muscle cramps, among others. Careful titration and monitoring are essential to optimize therapeutic outcomes while minimizing adverse effects. Pyridostigmine Bromide's efficacy and safety profile make it a valuable component in the therapeutic arsenal for conditions requiring enhanced cholinergic activity.

Formulas using

Pyridostigmine Bromide

Formulas and/or material listed are not to be interpreted as a promise, guarantee or claim of therapeutic efficacy or safety. The information contained herein is not intended to replace or substitute for conventional medical care, or encourage its abandonment. Every patient is unique, and formulas should be adjusted to meet their individual needs.

No compounded medications are reviewed by the FDA for safety or efficacy.